In bee sting anaphylaxis, the bee can be relied upon to inject into the skin 50 ug of venom -or something of that order -at a specific time, so that subsequent events can be observed with a fair degree of accuracy. Allergic reactions to bee stings thus offer an excellent opportunity for analysing the events that are associated with human anaphylaxis and with the methods used for its control.
The current availability of insect venoms for diagnosis and treatment has also led to a real advance in the clinical management of allergy, since controlled trials have now shown that venom immunotherapy can prevent anaphylactic reactions to subsequent stings (Hunt et al. 1978) . The evidence is more clear and unequivocal than for any other type of allergy. Furthermore, the isolation of phospholipase A and other allergenic components of venom has made it possible to develop specific tests for the antibodies that are involved in the venominduced allergic response, both as it occurs naturally and as it is modified in the course of immunotherapy. The immunological changes which accompany clinical improvement can thus be analysed in increasing detail.
Composition of venom
During the course of evolution, the venoms of stinging insects have developed as an injectable mixture of amines, peptides and enzymes, which are capable of disrupting a wide range of cell mechanisms. In addition to histamine, serotonin and acetylcholine, venoms contain kinins and various protein enzymes. These substances affect the rate of absorption of venom and so may modify the extent of the immunological stimulus. Individuals who become anaphylactically sensitized react, however, to quantities of allergenic proteins that are so small as to have little or no pharmacological effect. Phospholipase A (mol. wt 19500) makes up only 12% of the dried weight of bee venom, and hyaluronidase (mol. wt 50000) constitutes not more than 3% of the dried weight (King et al. 1976 ).These two enzymes appear to provide the main immunogens that are responsible for the majority of allergic reactions.
Clinical aspects
Despite earlier views to the contrary (Settipane et al. 1972) reactions to venom seem to occur more often in atopic than in non-atopic subjects (Miyachi et al. 1979) . There is, however, nearly always some local reaction to a sting and in some cases a very marked and persistent local effect heralds a more generalized reaction to subsequent stings. Within 30 minutes pruritus and urticaria, faintness and hypotension, respiratory difficulty and asthma, nausea, vomiting and diarrhoea can all occur. Cardiac arrhythmias have been noted in older patients and even children below the age of 10 can die from sting anaphylaxis (Jensen 1962).
Patients who have repeated generalized reactions come to recognize an aura which involves pulsating feelings in the ears, tightness of the throat, substernal pain and fear of impending death. In the most severe cases, the interval before these symptoms develop can steadily decrease until a patient may lose consciousness within minutes. It is in this group of patients that fatalities occur. Apart from classical anaphylaxis, a number of other types of reaction have been described, including a reaction resembling serum 'sickness, with joint pains and fever developing after an interval of some days and persisting for some weeks (Kaplan et a/. 1977) . Proteinuria is common but is usually short-lived. Haematuria is also recognized and so are vesicular skin eruptions of delayed onset. Peripheral neuropathy, intracranial haemorrhage or oedema, mental changes and myocardial infarction have all been thought, in a few instances, to be precipitated by bee stings in sensitized subjects. In some cases, as in the serum sickness type of reaction or where there is evidence of renal involvement, the suspicion of immune-complex-mediated disease is sufficiently strong to suggest that immunotherapy should be used with caution or not at all.
The emergency treatment of choice is still 0.5 ml of 1/1000 solution of adrenaline given by deep subcutaneous injection and repeated in 10 minutes. Failing this, a pressurized atomizer containing isoprenaline or adrenaline can be of value. Antihistamines and corticosteroids provide no immediate benefit (Austen 1978) but can undoubtedly mitigate the later symptoms and speed recovery.
Immunotherapy
Even in patients with a past history of anaphylactic reactions to bee stings, intradermal skin tests fail to show evidence of persisting sensitization in approximately one-third of patients (Hunt et al. 1978) . Even among the remainder, who have both a history of anaphylaxis and a positive skin test to venom, 40% do not react to a subsequent sting. This may account for past optimism about the beneficial effect of injections of bee body extracts. Even after an anaphylactic response and in the absence of all treatment, the natural history of the disease is benign in quite a high proportion of cases. Allergic beekeepers who expose themselves to further stings sometimes report a gradual lessening and finally a disappearance of all symptoms and even a fading of the local reaction, suggesting a 'natural' type of desensitization or immunotherapy. Mortality figures indicate that the course of bee sting allergy is by no means always so benign (Parrish 1959) . Thirteen percent of patients have a more severe reaction on being stung again (Settipane & Chafee 1979 ,Settipane & Boyd 1970 . In assessing the persisting risk of further reactions, skin tests have proved to be of considerable value (Miyachi et al. 1979 ) and a case can be made for treating all those whose history ofsystemic reactions to a bee sting is associated with a positive reaction to intradermal bee venom in a concentration of 0.1 micrograms or less.
In developing the practical aspects of this therapy, Lichtenstein and his colleagues (1979) have used 0.1 micrograms of bee venom as a starting dose, followed by two further doses of I microgram and 3 micrograms at 3D-minute intervals on the first day. By giving weekly injections subsequently, maintenance doses of 100 micrograms can often be reached within about six weeks, but some patients cannot proceed to monthly maintenance doses until they have increased slowly to this level over six months or even a year. As long as IgE antibody levels remain high, maintenance injections are then continued.
The results of treatment with bee venom and whole bee extract have now been compared (Hunt et al. 1978) . Of 19 patients who were studied after treatment with venom, only one had a reaction to a challenge sting under controlled conditions in a hospital ward. Of the 14 patients who failed to respond to treatment with whole body extract or placebo, 13 subsequently responded to venom immunotherapy and, when they were then stung, had no reaction. However, one out of six patients had a systemic reaction during therapy. It must therefore be accepted that this treatment carries some hazards and should be carried out only where supporting treatment is available in the event of an anaphylactic reaction.
Physiological basis of immunotherapy
The most intriguing aspect of this work lies in its possible implications for other types of immunotherapy. The superiority of bee venom over whole body extracts makes it clear, perhaps not surprisingly, that effective immunotherapy depends on the injection of material that has a high allergen content. This, however, says little about the immunological basis for the clinical protection that is achieved. The reason for the effectiveness of bee venom immunotherapy is still poorly understood.
On the available evidence, IgE antibody production is controlled by complex regulating mechanisms, some of which involve the action of suppressor lymphocytes (Katz 1979 , Katz et al. 1980 . This could explain why it is that, in mice, immunosuppressive treatment or the use of low doses of whole body irradiation can lead to an increase of IgE antibody production. It could also explain why large or repeated injections of antigen in high IgE-responding strains of mice leads to a suppression of the IgE response and a switch to the brisk production of IgG antibody. It has been suggested that in man, similarly, repeated doses of antigen can stimulate IgE suppressor mechanisms or that when there is IgG antibody production this may itself inhibit the further production of IgE.
As an explanation of the beneficial effects of treatment this hypothesis is inadequate, since clinically successful immunotherapy is not necessarily accompanied by a fall in IgE antibodies and cannot therefore depend simply on the induction of a state of tolerance (Foucard & Johansson 1978) . As an alternative, it has been proposed that the production ofIgG antibody has a crucial role and that antigen binding by IgG blocks the access of antigen to IgE. This, too, is an inadequate explanation, since in 15 children with bee sting allergy who were given immunotherapy in Germany, no correlation could be found between a given IgG antibody titre and the degree of clinical protection (Urbanek et al. 1979) . Furthermore, in spite of the suggestion that passive infusion of IgG antibody to bee venom can have a partial protective effect (Lessof et al. 1977) this has not been the general experience. In four patients with bee sting allergy who failed to respond to immunotherapy, a significant rise in their own serum IgG antibody to phospholipase A conferred no obvious protection (Yunginger & Santrach 1979) and the passive administration of further quantities of IgG antibody to phospholipase A by plasma transfusion also failed to prevent anaphylaxis after a bee sting. It is assumed that, in these cases, the allergic reaction was directed against phospholipase A and not against hyaluronidase or some other component and, if so, this shows that levels of blocking antibody do not always correlate with the beneficial effects of immunotherapy. It can only be surmised that, regardless of the blocking effects of other classes of antibody, central suppressor mechanisms help to regulate IgE antibody production and other components of the immune response, and that the development of anaphylaxis represents a failure of this type of 'selfregulation'. It remains to be established whether these mechanisms are also modified by circulating immune complexes, Katz's (1979) 'enhancing factor of allergy' or other influences. Whatever views may be held on this, if atopy involves a defective function of the immunological control system, the main aim of immunotherapy must be to stimulate the failing function of the body's IgE-suppressor system or to block its clinical effects. Other methods of manipulating the immune response have also been used. The suggestion has been made that chemically modified allergens can have a more potent effect than conventional immunotherapy and that modified allergens can suppress established IgE reactions (Kudo et al. 1978) . If current attempts to use 'venomoids' in this way are successful, this could result in an important change in the clinical approach.
The availability of venom for the treatment of bee sting allergy has thus improved the outcome for affected patients but left a number of important questions unanswered. The accurate monitoring of the patient's immunological response should help us to unravel the mechanisms by which immunotherapy achieves its results, but this will take time. Meanwhile, when allergists insist on injecting increasing quantities of allergenic material without explaining why they are doing so, it must be accepted that, against all expectation, this treatment method can sometimes be shown to be highly effective.
